Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 7/2022

22.03.2022 | Geriatric Oncology (L Balducci, Section Editor)

Treatment of Metastatic Melanoma in the Elderly

verfasst von: Rino S. Seedor, Marlana Orloff

Erschienen in: Current Oncology Reports | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This study aims to review the clinical experience of melanoma treatments in patients with advanced age.

Recent Findings

During the last decade, the treatment paradigm for melanoma has changed dramatically with the use of checkpoint inhibitors, oncolytic viruses, and targeted therapies. We reviewed both the clinical trial and real-world experience of these therapies in patients of advanced age, and discuss how a personalized approach should be taken for these patients with consideration of incidence and management of side effects.

Summary

Although special consideration should be taken, immunotherapy, oncolytic viruses, and targeted therapy have shown efficacy and tolerability in older patients with melanoma.
Literatur
1.
Howlander N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer statistics review, 1975-2018, National Cancer Institute. Bethesda, MD, https://​seer.​cancer.​gov/​csr/​1975_​2018/​, based on November 2020 SEER data submission, posted to the SEER Web site, April 2021.
2.
Bhatt VR, Shrestha R, Krishnamurthy J, Mosalpuria K, Loberiza FR, Ganti AK, et al. Clinicopathologic characteristics and management trends of cutaneous invasive and in situ melanoma in older patients: a retrospective analysis of the National Cancer Data Base. Ther Adv Med Oncol. 2015;7(1):4–11.PubMedPubMedCentralCrossRef
3.
Rogiers A, van den Oord JJ, Garmyn M, Stas M, Kenis C, Wildiers H, et al. Novel therapies for metastatic melanoma: an update on their use in older patients. Drugs Aging. 2015;32(10):821–34.PubMedCrossRef
4.
Bastiaannet E, Battisti N, Loh KP, de Glas N, Soto-Perez-de-Celis E, Baldini C, et al. Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. J Geriatr Oncol. 2019;10(3):389–97.PubMedCrossRef
5.
Iacono D, Vitale MG, Basile D, Pelizzari G, Cinausero M, Poletto E, et al. Immunotherapy for older patients with melanoma: from darkness to light? Pigment Cell Melanoma Res. 2021;34(3):550–63.PubMedCrossRef
6.
Conway WC, Faries MB, Nicholl MB, Terando AM, Glass EC, Sim M, et al. Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol. 2009;16(6):1548–52.PubMedPubMedCentralCrossRef
7.
•• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol. 2021;39(15_suppl):9506. Practice changing study of the combination of ipilimumab and nivolumab therapy improving overall survival in advanced melanoma, with an impressive median OS of 72.1 months.CrossRef
8.
Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, et al. NCCN Guidelines(R) insights: older adult oncology, Version 1.2021. J Natl Compr Cancer Netw. 2021;19(9):1006–19.CrossRef
9.
10.
Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061–7.PubMedCrossRef
11.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.PubMedPubMedCentralCrossRef
12.
13.
Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.PubMedCrossRef
14.
Lawrence D, McDermott DF, Hamid O, Weber JS, Wolchok JD, Richards J, et al. Ipilimumab (IPI) expanded Access Program (EAP) for patients (PTS) with stage III/IV melanoma: safety data by subgroups. Ann Oncol. 2012;23:ix368.CrossRef
15.
Berrocal A, Arance A, Lopez Martin JA, Soriano V, Muñoz E, Alonso L, et al. Ipilimumab for advanced melanoma. Melanoma Res. 2014;24(6):577–83.PubMedPubMedCentralCrossRef
16.
Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res. 2014;33(1):30.PubMedPubMedCentralCrossRef
17.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–8.PubMedPubMedCentralCrossRef
18.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.PubMedCrossRef
19.
Singh H, Kim G, Maher VE, Beaver JA, Pai-Scherf LH, Balasubramaniam S, et al. FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. J Clin Oncol. 2016;34(15_suppl):10010.CrossRef
20.
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.PubMedCrossRef
21.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.PubMedPubMedCentralCrossRef
22.
Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480–92.PubMedCrossRef
23.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46.PubMedCrossRef
24.
•• Lipson EJ, Tawbi HA-H, Schadendorf D, Ascierto PA, Matamala L, Gutiérrez EC, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol. 2021;39(15_suppl):9503. A new combination of a LAG-3 inhibitor and PD-1 inhibitor that showed PFS benefit over nivolumab alone, with toxicity rates similar to nivolumab alone.CrossRef
25.
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.PubMedCrossRef
26.
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–36.PubMedCrossRef
27.
28.
29.
30.
Dummer R, Flaherty K, Robert C, Arance AM, Groot JW, Garbe C, et al. Five-year overall survival (OS) in COLUMBUS: a randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. J Clin Oncol. 2021;39(15_suppl):9507.CrossRef
31.
32.
33.
Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436–44.PubMedCrossRef
34.
Ascierto PA, Dréno B, Larkin J, Ribas A, Liszkay G, Maio M, et al. 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation–positive advanced melanoma: extended follow-up of the coBRIM study. Clin Cancer Res. 2021;27(19):5225–35.PubMedCrossRef
35.
• Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835–44. This study combined a BRAF inhibitior, MEK inhibitor, and PD-L1 inhibitor and found a PFS benefit but with significant toxicity.PubMedCrossRef
36.
Perier-Muzet M, Gatt E, Peron J, Falandry C, Amini-Adle M, Thomas L, et al. Association of immunotherapy with overall survival in elderly patients with melanoma. JAMA Dermatol. 2018;154(1):82–7.PubMedCrossRef
37.
Ibrahim T, Mateus C, Baz M, Robert C. Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. Cancer Immunol Immunother. 2018;67(10):1571–8.PubMedCrossRef
38.
Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist. 2017;22(8):963–71.PubMedPubMedCentralCrossRef
39.
Friedman CF, Horvat TZ, Minehart J, Panageas K, Callahan MK, Chapman PB, et al. Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+). J Clin Oncol. 2016;34(15_suppl):10009.CrossRef
40.
Mian I, Yang M, Zhao H, Shah M, Diab A, Shannon V, et al. Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab. J Clin Oncol. 2016;34(15_suppl):3047.CrossRef
41.
• Becquart O, Oriano B, Dalle S, Mortier L, Leccia MT, Dutriaux C, et al. Tolerance and effectiveness of targeted therapies in aged patients with metastatic melanoma. Cancers (Basel). 2021;13(12). This study is one of the few published real-world experiences on BRAF and MEK inhibitor therapy in older patients with advanced melanoma; PFS and OS were similar but grade 3-4 toxicities were increased in older patients.
42.
Freeman M, Weber J. Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma. J ImmunoTherapy Cancer. 2015;3(S2):P133.CrossRef
43.
Kleemann J, Jager M, Valesky E, Kippenberger S, Kaufmann R, Meissner M. Real-world experience of talimogene laherparepvec (T-VEC) in old and oldest-old patients with melanoma: a retrospective single center study. Cancer Manag Res. 2021;13:5699–709.PubMedPubMedCentralCrossRef
44.
Zhou AY, Wang DY, McKee S, Ye F, Wen CC, Wallace DE, et al. Correlates of response and outcomes with talimogene laherperpvec. J Surg Oncol. 2019;120(3):558–64.PubMedPubMedCentralCrossRef
45.
Archibald WJ, Victor AI, Strawderman MS, Maggiore RJ. Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: the Wilmot Cancer Institute experience. J Geriatr Oncol. 2020;11(3):496–502.PubMedCrossRef
46.
Kapoor V, Rixe O. Toxicity of PD-1/CTLA-4 inhibitor immunotherapy among elderly patients. J Clin Oncol. 2019;37(15_suppl):e14139-e.CrossRef
47.
Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.PubMedCrossRef
48.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801.PubMedCrossRef
49.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.PubMedCrossRef
50.
Dummer R, Hauschild A, Santinami M, Atkinson V, Mandala M, Kirkwood JM, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383(12):1139–48.PubMedCrossRef
51.
• Ikeguchi A, Machiorlatti M, Vesely SK. Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. Melanoma Manag. 2020;7(2):MMT43. A large analysis of the National Cancer Database for stage III patients treated with adjuvant immunotherapy found greater improvement in OS with older patients.PubMedPubMedCentralCrossRef
52.
• Overcash J, Ford N, Kress E, Ubbing C, Williams N. Comprehensive geriatric assessment as a versatile tool to enhance the care of the older person diagnosed with cancer. Geriatrics (Basel). 2019;4(2). This editorial details the components of a Comprehensive Geriatric Assessment and how it can be implemented into practice.
53.
Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326–47.PubMedPubMedCentralCrossRef
54.
Dotan E, Walter LC, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, et al. NCCN Clinical practice guidelines in oncology: older adult oncology. Version 1.2020. 2020. Available from: NCCN.​org.
55.
Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998–2005.PubMedCrossRef
56.
Clough-Gorr KM, Thwin SS, Stuck AE, Silliman RA. Examining five- and ten-year survival in older women with breast cancer using cancer-specific geriatric assessment. Eur J Cancer. 2012;48(6):805–12.PubMedCrossRef
57.
Hurria A, Cirrincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29(10):1290–6.PubMedPubMedCentralCrossRef
58.
Hurez V, Padron AS, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol. 2017;187(1):53–63.PubMedCrossRef
59.
Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2017;8:1960.PubMedCrossRef
Metadaten
Titel
Treatment of Metastatic Melanoma in the Elderly
verfasst von
Rino S. Seedor
Marlana Orloff
Publikationsdatum
22.03.2022
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 7/2022
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-022-01257-5

Weitere Artikel der Ausgabe 7/2022

Current Oncology Reports 7/2022 Zur Ausgabe

Anesthesiology and Critical Care (JP Cata, Section Editor)

The Role of Hyperthermia in the Treatment of Peritoneal Surface Malignancies

Melanoma (DB Johnson, Section Editor)

Anti-PD-1: When to Stop Treatment

Cardio-oncology (JN Upshaw, Section Editor)

Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge

Breast Cancer (RA Leon Ferre, Section Editor)

Bystander effect of antibody–drug conjugates: fact or fiction?

Leukemia (A Aguayo, Section Editor)

Antibiotic Management of Patients with Hematologic Malignancies: From Prophylaxis to Unusual Infections

Pediatric Oncology (KL Davis, Section Editor)

Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise